Immunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art
Open accessThe DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
Abstract
Around 1–5% of all couples experience recurrent pregnancy loss (RPL). Established risk factors include anatomical, genetic, endocrine, and hemostatic alterations. With around 50% of idiopathic cases, immunological risk factors are getting into the scientific focus, however international guidelines hardly take them into account. Within this review, the current state of immunological risk factors in RPL in international guidelines of the European Society of Reproduction and Embryology (ESHRE), American Society of Reproductive Medicine (ASRM), German/Austrian/Swiss Society of Obstetrics and Gynecology (DGGG/OEGGG/SGGG) and the Royal College of Obstetricians and Gynecologists (RCOG) are evaluated. Special attention was drawn to recommendations in the guidelines regarding diagnostic factors such as autoantibodies, natural killer cells, regulatory T cells, dendritic cells, plasma cells, and human leukocyte antigen system (HLA)-sharing as well as treatment options such as corticosteroids, intralipids, intravenous immunoglobulins, aspirin and heparin in RPL. Finally, the current state of the art focusing on both diagnostic and therapeutic options was summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, the significance of increased peripheral NK cells remains debatable, 101 as they do not appear to reflect the levels in the endometrium, 102 show an intracycle, hormonal and ethnic variability, 103 and appear not to predict subsequent miscarriage in a population of women with recurrent miscarriage.104”
From Recurrent MiscarriageGreen‐top Guideline No. 17 (2023) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203 · cited 1×
“, 2 pregnancy losses or antibody titres in the lower range) (Table 2) [42].”
BackgroundPark, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731 · cited 1×
“Thyroid autoimmunity is associated with adverse pregnancy outcomes such as preterm delivery and pregnancy loss, as well as infertility [43].”
BackgroundDecidual NK cells regulate key developmental processes at the human fetal-maternal interface
Hanna, J., Goldman-Wohl, D., Hamani, Y., Avraham, I., Greenfield, C., Natanson-Yaron, S., Prus, D., Cohen-Daniel, L., Arnon, T. I., Manaster, I., et al. (2006) · Nature Medicine · doi:10.1038/nm1452 · Cited by 1,681
EULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, M. G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., Cuadrado, M. J., Dörner, T., Ferrer-Oliveras, R., Hambly, K., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215213 · Cited by 1,318
Evaluation and treatment of recurrent pregnancy loss: a committee opinion
(2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.048 · Cited by 1,308
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274 · cited 4×
“If TSH levels are >2.5 mU/L, T3, T4 and thyroid autoantibody concentrations should be determined A ll oi m m un e R is k Fa ct or s Im m un e C el ls Controversial scientific evidence for dendritic cells or regulatory T-cells Most data available for uNKs, is controversial and testing can only be recommended within stu…”
BackgroundInfluential
Cited by
Turesheva, A., Aimagambetova, G., Ukybassova, T., Marat, A., Kanabekova, P., Kaldygulova, L., Amanzholkyzy, A., Ryzhkova, S., Nogay, A., Khamidullina, Z., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12124074 · Cited by 174
Immune determinants of endometrial receptivity: a biological perspective
Robertson, S. A., Moldenhauer, L. M., Green, E. S., Care, A. S., & Hull, M. L. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.04.023 · Cited by 176
Recurrent MiscarriageGreen‐top Guideline No. 17
Regan, L., Rai, R., Saravelos, S., Li, T., & the Royal College of Obstetricians and Gynaecologists (2023) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17515 · Cited by 158
Cao, C., Bai, S., Zhang, J., Sun, X., Meng, A., & Chen, H. (2022) · Medical Review · doi:10.1515/mr-2022-0030 · Cited by 112
“Studies have paidmore attention to investigate the RPL-related immunological risk factors, such as autoantibodies, peripheral and uterineNK-cells, and regulatory T cells [102].”
BackgroundDecidual macrophages in recurrent spontaneous abortion
Zhao, Q., Li, Q.-H., Fu, Y., Ren, C., Jiang, A., & Meng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.994888 · Cited by 102
“Given the relationship with RSA, researches mostly support that the immunological factor is a prerequisite for a successful pregnancy (11).”
BackgroundGenetic causes of sporadic and recurrent miscarriage
Melo, P., Dhillon‐Smith, R. K., Islam, M. A., Devall, A., & Coomarasamy, A. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.08.952 · Cited by 71
The Diagnostics and Treatment of Recurrent Pregnancy Loss
Tomkiewicz, J., & Darmochwał-Kolarz, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144768 · Cited by 62
“There is no unequivocal evidence of the impact of antinuclear antibodies (ANA) on RPL: at the moment, no international guidelines recommend routine ANA testing; only the latest ESHRE guidelines include testing for explanatory purposes [3,4,53].”
BackgroundPleguezuelo, D. E., Cabrera-Marante, Ó., Abad, M., Rodriguez-Frias, E. A., Naranjo, L., Vázquez, A. F., Villar, O., Gil‐Etayo, F. J., Serrano, M., Pérez‐Rivilla, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102094 · Cited by 38
Special Issue Recurrent Pregnancy Loss: Etiology, Diagnosis, and Therapy
Christiansen, O. B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215040 · Cited by 33
Liu, H., Zheng, J., & Liao, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988130 · Cited by 35
Lin, M., Xu, H., & Qiu, J. (2024) · Ginekologia Polska · doi:10.5603/gpl.97320 · Cited by 27
The microbiome in recurrent pregnancy loss – A scoping review
Vomstein, K., Krog, M. C., Wrønding, T., & Nielsen, H. S. (2024) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2024.104251 · Cited by 28
Self-citationBraun, A.-S., Vomstein, K., Reiser, E., Tollinger, S., Kyvelidou, C., Feil, K., & Tóth, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175585 · Cited by 26
“Broad immunotherapy with corticosteroids for RIF or RPL lacks strong evidence to support its routine use, mainly due to small and inconsistent study groups and patient selection [6,34,35].”
BackgroundSelf-citationAllogeneic lymphocytes immunotherapy in female infertility: Lessons learned and the road ahead
Sarkesh, A., Sorkhabi, A. D., Ahmadi, H., Abdolmohammadi‐Vahid, S., Parhizkar, F., Yousefi, M., & Maleki, L. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120503 · Cited by 26
Diagnostic factors for recurrent pregnancy loss: an expanded workup
Ticconi, C., Nicastri, E., D’Ippolito, S., Chiaramonte, C., Pietropolli, A., Scambia, G., & Simone, N. D. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07001-z · Cited by 25
“Recurrent pregnancy loss (RPL), defined as the spontaneous loss of two or more pregnancies [1] or the loss of two or more pregnancies before the 24th week of gestation [2], is a relevant complication of pregnancy affecting up to 5% of the couples of reproductive age [3].”
BackgroundLi, Q.-H., Zhao, Q., Yang, W., Jiang, A., Ren, C., & Meng, Y. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s459263 · Cited by 22
“173 176”
Immune Cell Functionality during Decidualization and Potential Clinical Application
Stope, M. B., Mustea, A., Sänger, N., & Einenkel, R. (2023) · Life · doi:10.3390/life13051097 · Cited by 20
Li, M., Zhou, R., Yu, D., Chen, D., & Zhao, A. (2024) · Human Reproduction · doi:10.1093/humrep/deae181 · Cited by 21
Issakhanova, A., Issanov, A., Ukybassova, T., Kaldygulova, L., Marat, А., Imankulova, B., Kamzayeva, N., Almawi, W. Y., & Aimagambetova, G. N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020658 · Cited by 20
Jameel, S., Bhuwalka, R., Begum, M., Bonu, R., & Jahan, P. (2024) · Reproductive Biology · doi:10.1016/j.repbio.2023.100842 · Cited by 17
Vomstein, K., Egerup, P., Kolte, A. M., Behrendt-Møller, I., Boje, A. D., Bertelsen, M.-L. M. F., Eiken, C. S., Reiersen, M. R., Tóth, B., Freiesleben, N. L. C., et al. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.03.018 · Cited by 16
Self-citationbalawi, A. N. A., Alblwi, N. A. N., Soliman, R., El‐Far, A. H., Hassan, M. G., El-Sewedy, T., Ameen, F., Ismail, N. F., & Elmetwalli, A. (2024) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-024-06914-0 · Cited by 16
“Certain medical conditions, such as autoimmune, thyroid, or clotting disorders, can increase RPL risk [5].”
BackgroundAsghari, K. M., Novinbahador, T., Mehdizadeh, A., Zolfaghari, M. A., & Yousefi, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39584 · Cited by 18
Tóth, E., Györffy, D., Posta, M., Hupuczi, P., Balogh, A., Szalai, G., Orosz, G., Orosz, L., Szilágyi, A., Oravecz, O., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031865 · Cited by 15
D’Ippolito, S., Gavi, F., Granieri, C., de Waure, C., Giuliano, S., Cosentino, F., Tersigni, C., Scambia, G., & Simone, N. D. (2025) · American Journal of Reproductive Immunology · doi:10.1111/aji.70037 · Cited by 15
Shargorodska, E. B., & Melenchuk, L. M. (2022) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.22.2.116 · Cited by 14
Cavalcante, M. B., da Silva, P. H. A., Sampaio, O. G. M., Câmara, F. E. A., Cavalcante, C. T. D. M. B., & Barini, R. (2023) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2023.103986 · Cited by 17
Moini, A., Sepidarkish, M., Dehpour, A. R., Rabiei, M., Abiri, A., & Pirjani, R. (2022) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2022.2141615 · Cited by 13
“In terms of possible maternal factors involved in URPL, various pharmacological factors such as aspirin, corticosteroids, progesterone, IVIG and anticoagulants have been studied (Vomstein et al. 2021), however, their effect on preventing URPL is not proven.”
BackgroundHigh maternal-fetal HLA eplet compatibility is associated with severe manifestation of preeclampsia
Stefanska, K. A., Kurkowiak, M., Piekarska, K., Chruściel, E., Zamkowska, D., Jassem-Bobowicz, J. M., Adamski, P., Świątkowska−Stodulska, R., Abacjew-Chmyłko, A., Leszczyńska, K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272021 · Cited by 12
“Approximately 50% of idiopathic cases of recurrent miscarriages have immune etiology (35, 36).”
BackgroundGarmendia, J. V., & Sanctis, J. B. D. (2021) · Immuno · doi:10.3390/immuno1030011 · Cited by 10
Wang, L., Jiang, Y., Shen, H., Ma, X., Gao, M., Jin, P., Zhang, R., Zhao, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992121 · Cited by 9
Recent Advances in Immunotherapeutic Approaches for Recurrent Reproductive Failure
Abdolmohammadi‐Vahid, S., Maleki, L. A., Heris, J. A., Danaii, S., & Yousefi, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.108869 · Cited by 9
Mahdi, E. E., Fekry, N., Ahmed, M. N., & Ghebremeskel, K. (2023) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2022.2163625 · Cited by 7
“2021, Vomstein et al .”
BackgroundNajjar, A. A., Hassouna, I. A., Srour, M. A., Ibrahim, H. M., Assi, R. Y., & Latif, H. M. A. E. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-05764-6 · Cited by 8
“The maternal immune system does not ignore the fetus, but first recognizes and then responds to the employee antigens during development, and the physiological maternal tolerance towards the embryo ensures a successful pregnancy [8].”
BackgroundAnsariniya, H., Hadinedoushan, H., Zare, F., Idali, F., Shabani, M., & Mosaffa, N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110908 · Cited by 7
Immunological Risk Factors in Recurrent Pregnancy Loss in Patients With Hereditary Thrombophilia
Kirovakov, Z., Konova, E. I., Hinkova, N., Markova, S., & Пенчев, П. (2024) · Cureus · doi:10.7759/cureus.56555 · Cited by 7
“The focus of this study is on immunological factors, which include a wide range of mechanisms from immune tolerance to immune dysregulation, each of which significantly impacts the outcome of pregnancy [7,8].”
BackgroundCommon Autoimmune Antibodies in Unexplained Infertile Female Patients in Saudi Arabia
Koshak, E. A., Atwah, A. F., Aljedani, R., Aljaied, Y., & Gaddoury, M. A. (2022) · Cureus · doi:10.7759/cureus.31724 · Cited by 7
“Nevertheless, the American and European societies for reproduction recommend screening for antiphospholipid antibodies only after two pregnancy losses, while many European societies of obstetricians and gynecologists recommend this investigation after three pregnancy losses [14].”
BackgroundBetti, M., Vizza, E., Piccione, E., Pietropolli, A., Chiofalo, B., Pallocca, M., & Bruno, V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1082087 · Cited by 8
“Dysregulation of the maternal immune response to fetal/trophoblast antigens has been demonstrated, including through killer immunoglobulin-like receptor (KIR), human leukocyte antigen (HLA), mannose‐binding lectin (MBL) and H-Y antigen regulation (14, 15).”
BackgroundExploring novel molecular mechanisms underlying recurrent pregnancy loss in decidual tissues
Ding, H., Gao, Y., Gao, Y., Chen, Y., Liu, R., Wang, C., & Gao, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-10604-y · Cited by 6
“Maternal immune tolerance, which is essential for successful pregnancy 41,42 is disrupted in RPL due to abnormal immune cell infiltration.”
Endometrial immune profile: A predictor of pregnancy success
Baharaghdam, S., Karimi, S., Farahani, M. E., Maleki, L. A., & Yousefi, M. (2025) · Reproductive Biology · doi:10.1016/j.repbio.2025.101174 · Cited by 6
Murad, H., Ali, B., Twair, A., Baghdadi, K., Alhalabi, M., & Abbady, A. Q. (2023) · Scientific Reports · doi:10.1038/s41598-023-49768-w · Cited by 6
Pregnancy, a test case for immunology
Devanesan, A. (2024) · Synthese · doi:10.1007/s11229-023-04444-4 · Cited by 6
“Yet this is detrimental to foetal implantation (Beydoun & Saftlas, 2005; Chaouat, 1993; Creus et al., 1998; Vomstein et al., 2021).”
Immunologic Factors and Genomic Considerations in Recurrent Pregnancy Loss: A Review
Montazeri, F., Tajamolian, M., Hosseini, E. S., & Hoseini, S. M. (2024) · International Journal of Medical Laboratory · doi:10.18502/ijml.v10i4.15010 · Cited by 8
Finan, R. R., Beydoun, N., Racoubian, E., Bahia, W., Ferchichi, S., & Almawi, W. Y. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01725-2 · Cited by 5
“Various risk factors contribute to RPL, including environmental, genetic, anatomical, endocrine, and immunological elements [2, 4].”
Ebrahimi, R., Asghari, K. M., Alamdary, S. J., Kamrani, A., Soltani‐Zangbar, M. S., Danaii, S., Aliasgharzadeh, A., Heris, J. A., Maleki, L. A., Hojjat‐Farsangi, M., et al. (2025) · Human Immunology · doi:10.1016/j.humimm.2024.111229 · Cited by 5
de la Fuente, E., Subhi‐Issa, N., Villegas-Mendiola, Á., Palacios-Ortega, M., Ochoa‐Grullón, J., Guevara‐Hoyer, K., Laborda, R. G., Pilar‐Suárez, L., Ruíz, M. D. M., Escorial, M. P. G., et al. (2025) · Medwave · doi:10.5867/medwave.2025.05.3037 · Cited by 5
Tóth, E., Posta, M., Györffy, D., Oravecz, O., Farkas, E., Balogh, A., Escher, C., Bober, M., Szilágyi, A., Hupuczi, P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621168 · Cited by 5
Han, N., Xia, W., Zhu, C., Zhang, X., Wang, F., Yin, Z., & Zeng, Q. (2023) · American Journal of Reproductive Immunology · doi:10.1111/aji.13792 · Cited by 5
Park, J. C., Han, J. W., & Lee, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90805-4.00019-5 · Cited by 10
Recurrent pregnancy loss - a life changing condition for women
Bălălău, D.-O., Augustin, F.-E., Bogheanu, D.-M., Negulescu, A.-G., Sima, R., Dumitriu, A. S., Păunica, S., & Pleș, L. (2023) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1384 · Cited by 4
“When it comes to which of these antibodies women should be tested for, the ESHRE guideline recommends screening for LA and ACA (Ig G and Ig M) as there is a body of evidence that proves a significant association of them with RPL [2].”
BackgroundInfluentialDing, H. Q., & An, G. (2023) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2023.2280840 · Cited by 4
“…such as plasma cells, natural killer cells, autoantibodies, dendritic cells, human leukocyte antigen system-sharing and regulatory T cells (Treg), accompanied by treatment options such as intravenous immunoglobulin, intralipid injection, corticosteroids, heparin and aspirin (Vomstein et al. 2021).”
BackgroundXie, Q., Zhang, L., Yang, J., Yang, M., Li, Q., & Chen, Q. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s554069 · Cited by 4
Research progress of immune balance and genetic polymorphism in unexplained recurrent abortion
Kang, Y., Xie, Q., Chen, S., Li, Q., Dong, X., Zhang, T., Fu, S., Lei, Q., & Huang, D. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00113 · Cited by 4
Koshak, E. A., Aljohani, H. S., Atwah, A. F., Aljedani, R., Aljaied, Y., & Gaddoury, M. A. (2023) · Cureus · doi:10.7759/cureus.48322 · Cited by 4
“Nevertheless, several societies recommend some immunological testing (mainly autoantibodies) for patients with recurrent pregnancy loss [10].”
BackgroundThe Impact of Inherited Thrombophilia on First Trimester Combined Aneuploidy Screening Parameters
Kirovakov, Z., Hinkova, N., & Konova, E. I. (2024) · Acta Medica Bulgarica · doi:10.2478/amb-2024-0073 · Cited by 3
“…that can be tested during the (cid:191) rst trimester include the pregnancy-associated plasma protein A (PAPP-A), human chorionic gonadotropin (hCG), and the nuchal translucency (NT), and the collection of the blood for testing should be done between 11 +0 and 13 +6 weeks of gestation [13, 14].”
InfluentialHu, F., Yang, C., Dai, L., Gao, D., Luo, H., Zhong, X., Chen, P., Zhu, L., Xiao, Z., Zhao, S., et al. (2025) · American Journal of Reproductive Immunology · doi:10.1111/aji.70105 · Cited by 3
“…as lymphocyte immunization, intravenous immunoglobulin, tumor necrosis factor-α inhibitor, and hydroxychloroquine therapies, as treatment for unexplained RPL, there exists no evidence supporting their efficacy and safety, and international guidelines for treatment do not recommend them [26–29].”
Dzirba, D., Glinko, M., Skoczyńska, M., Gruszecka, K., Trzeszcz, M., Benedyczak, A., & Szmyrka−Kaczmarek, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155172 · Cited by 3
“Unfortunately, there have been inconsistent results published from randomized placebo-controlled and randomized controlled treatment trials (RCTs) investigating the effect of IVIG on the live birth ratio (LBR) in RPL (recurrent pregnancy loss) patients [81].”
Study on the Relationship between Unexplained Recurrent Abortion and HLA-DQ Gene Polymorphism
Tang, J., Zhu, J., Shu, L., Huang, X., & Ma, S. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/8005538 · Cited by 3
RetractedIVF Technologies and Infertility - Current Practices and New Perspectives
Vladimirov, I. K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102193 · Cited by 4
Features of the state of extraembryonic structures in miscarriage early terms of pregnancy
Кравченко, О. В. (2024) · The Journal of V N Karazin Kharkiv National University series Medicine · doi:10.26565/2313-6693-2024-48-01 · Cited by 3
Farazmand, T., Rahbarian, R., Jalali, M., Ghahremani, A., Razi, A., & Ahmadabad, H. N. (2024) · PubMed Central · doi:10.22088/cjim.15.2.266 · Cited by 5
“Among several immunological factors associated with RPL, several studies suggest that autoimmune factors can cause fetal rejection in 30% of women with RPL (7, 8).”
BackgroundNew aspects of immunological risk factors in the treatment of recurrent pregnancy loss
Aliyeva, G., Tarverdiyeva, S., & Ibrahimov, M. (2024) · Healthcare in Low-resource Settings · doi:10.4081/hls.2024.12563 · Cited by 3
Endometrial scratching and intralipid treatment—no general recommendations
Mrosk, P., Sandi-Monroy, N. L., Gagsteiger, F., Friedl, T. W. P., Hancke, K., & Bundschu, K. (2024) · Frontiers in Reproductive Health · doi:10.3389/frph.2024.1505842 · Cited by 2
“However, so far presented data on uNK cells are controversial, not only due to missing standardized diagnostic but also proper reference amounts (40).”
Thabet, M., Hasan, K. A., Elhefnawy, I. A., Barakat, G., Moemen, D., Ragab, A., Elsherbini, D. M. A., El‐Sherbiny, M., Bahgat, N. A., Elshamy, M. R., et al. (2025) · Libyan Journal of Medicine · doi:10.1080/19932820.2025.2472492 · Cited by 2
“The World Health Organization (WHO) defines RPL as three or more consecutive pregnancy losses before the 20 th week of pregnancy [3].”
Zhang, Y., Alzahrani, M., Luu, T. V., Fatunbi, J., Ganieva, U., Bilal, M. Y., Thees, A. V., Gonzalez, M. F., Hawryluk, D., Dambaeva, S. V., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf283 · Cited by 2
Gkoltsos, C., Gastaldon, C., SKALKIDOU, A., Ehrt‐Schäfer, Y., Ochsenbein-Koelble, N., Barbui, C., Seifritz, E., & Schoretsanitis, G. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.034 · Cited by 2
Association of the thyroid Function disorder with recurrent pregnancy loss in women
Naeem, A., Heema, Jan, S., & Shah, B. G. (2022) · Pakistan BioMedical Journal · doi:10.54393/pbmj.v5i7.687 · Cited by 5
Che, X., Wang, X., Wang, L., Xu, L., Zou, L., Ma, T., & Chen, B. (2024) · Clinics · doi:10.1016/j.clinsp.2024.100327 · Cited by 2
Hamed, S., Shedid, A., Abdel-Halim, G., & Zainel-Din, A. Q. M. (2024) · Evidence Based Women s Health Journal · doi:10.21608/ebwhj.2023.245173.1269 · Cited by 2
“%) lack identifiable causes [4] .”
Zhou, H., Zou, Y., Guo, Y., Lv, X., Chen, J., Guo, X., & Liu, Q. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110596 · Cited by 2
Wang, L., Jiang, Y., Luo, X., Shen, H., Yu, L., Yang, X., Wang, H., Jin, P., & Zhang, X. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01576-x · Cited by 1
Frühschwangerschaft: klinische Aspekte und Abortgeschehen
von Steinburg, S. P. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-63506-3_2 · Cited by 1
Velikova, T. V., Tomov, L., & Nikolaev, G. (2024) · Targets · doi:10.3390/targets2040017 · Cited by 1
Chang, Z., Li, L.-H., Lv, L.-Z., Wang, Z., Wang, Q., Zhu, H., Jiang, B., Zhou, X.-M., Han, Y., Pan, X., et al. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2025.1720842 · Cited by 1
Kong, F., Yin, Z., Zhou, H., Liu, Z., & Xie, W. (2026) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.70220 · Cited by 1
“However, when referencing the diagnostic guidelines of the American Society for Reproductive Medicine (ASRM), ESHRE or the Royal College of Obstetricians and Gynecologists (RCOG), over 50% of cases are still unexplained (Colley et al. 2019; Vomstein et al. 2021).”
Dryllis, G., Giannikos, T., Konstantinou, E. A., Moustakas, I., Christopoulos, P., Pittaras, T., Politou, M., & Valsami, S. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.933746 · Cited by 2
“However, except for antiphospholipid syndrome, the real role of immunologic disorders, possibly PPBL, in recurrent pregnancy losses remains unclear [16].”
BackgroundInfluentialRecurrent Pregnancy Loss and Associated Risk Factors
Bano, N., Naeem, A., Mubashir, H., Tufail, N., Shafiq, S., & Shaikh, F. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22169586 · Cited by 1
Study Imbalance of Some Cytokines and Vaginitis Agents in Women with Recurrent Abortion Women
Al-sallami, M. H., Al-Salihi, S. A. A. H. O., & Darweesh, M. F. (2024) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_1097_23 · Cited by 2
Wen, X., Chen, X., Li, M., Zhou, J., Dao, S. Z., Li, S., Cheng, H., Zhao, S., & Huang, G. (2025) · PubMed Central · doi:10.22074/ijfs.2024.2011343.1541 · Cited by 1
Gadwal, B. M., Rajan, R. S., & Rao, K. A. (2021) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20213483
“5 mU/l should be considered as an abnormal result in RPL patients.(26) Glycemic control and insulin sensitivity are the most critical factors in reproductive pathophysiology.”
Fathy, S. A. M., Eltemamy, E. A., & Mohamed, M. F. (2022) · Al-Azhar Medical Journal · doi:10.21608/amj.2022.230467 · Cited by 1
Laboratory approaches for reproductive failure: immunological biomarkers for reproductive failures
Wolf, K., Beaman, K. D., Dambaeva, S. V., & Gilman‐Sachs, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90805-4.00027-4
Role of the Proper Nutrition for Indian Women with Recurrent Pregnancy Loss (RPL)
Banerjee, S. (2022) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.31.1.9
Frühschwangerschaft: klinische Aspekte und Abortgeschehen
von Steinburg, S. P. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-44369-9_2-2
Recurrent Miscarriage: A machine learning approach to uncover key genes and immune InfiltrationPreprint
Lin, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3240374/v1
Würfel, W. (2023) · Springer eBooks · doi:10.1007/978-3-662-63907-8_13
Евгеньевна, Т. И., Malyshkina, A. I., Sotnikova, N. Y., Владимировна, К. Н., Grigushkina, E. V., & Pesikin, R. O. (2023) · Russian Journal of Human Reproduction · doi:10.17116/repro20232905118
Dryllis, G., Giannikos, T., Konstadinou, E., Moustakas, I. I., Christopoulos, P., Pittaras, T., Politou, M., & Valsami, S. I. (2024) · Authorea · doi:10.22541/au.170665873.31012005/v1
Pota, Ç. E., Doğan, M. E., Sanhal, C. Y., & Pota, A. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07549-4
The Role of Immunotherapy in the Treatment of Recurrent Miscarriage
Panah, S. R., & Mohammadi, H. (2023) · ملیون. · doi:10.61186/sjrm.8.1.43
Patel, N., Patel, N., Patel, M. N., Bhadarka, H. K., Ghoghari, P., Dhaduk, S., Chudasama, P., & Vyas, K. (2024) · Research Square · doi:10.21203/rs.3.rs-5403424/v1
Tnf-α inhibition and treatment of recurrent pregnancy loss
Shafi, H., Manzoor, H., Lone, S. S., & Wani, J. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13657-3.00007-6
Production of autoimmune antibodies and recurrent pregnancy loss
Agrawal, R., Sharma, Y., Rajpal, C., Sanganabhatla, D., Sachan, S., Khan, B., & Ghongade, H. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13617-7.00016-5
Role of JAK-STAT signaling pathway in recurrent pregnancy loss
Zubair, S., Khan, N. A., Sharma, S., Khera, N., & Rashid, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13617-7.00013-x
Immunopathology at the Maternal-fetal Interface: Autoimmune Disorders and Recurrent Pregnancy Loss
Mukhopadhaya, N., & Nandi, M. (2025) · International Journal of Recurrent Pregnancy Loss · doi:10.5005/ijrpl-11032-0007
Recurrent miscarriage: strategies for overcoming the problem in the pre-pregnancy stage
Жабченко, И. А., Ліхачов, В. К., Korniets, N. G., Lishchenko, I. S., & Dobrovolska, L. М. (2025) · Reproductive Endocrinology · doi:10.18370/2309-4117.2025.79.39-50
Xuan, J., Chen, Y., He, X., Huang, L., & Wei, X. (2025) · Ginekologia Polska · doi:10.5603/gpl.105037
Huo, H., Hu, N., Yang, Y., Liu, L., Mu, F., & Wang, F. (2025) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.70152
“Biochemical pregnancies are marked by transient elevations in serum human chorionic gonadotropin levels, in the absence of a detectable gestational sac via ultrasonography, culminating in an unobserved pregnancy loss, alternately termed as pregnancies of unknown location or cryptic abortions [7, 8].”
Najjar, A. A., Hassouna, I. A., Srour, M. A., Ibrahim, H. M., Assi, R. Y., & Latif, H. M. A. E. (2024) · Figshare · doi:10.6084/m9.figshare.26598530
Metadata
- Authors
- Vomstein, K., Feil, K., Strobel, L., Aulitzky, A., Hofer-Tollinger, S., Kuon, R.-J., & Toth, B.
- Affiliations
- Innsbruck Medical University (AT)
- Heidelberg University (DE)
- Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
- Corresponding author
- Vomstein, Kilian
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-02-20
- Volume
- 10
- Issue
- 4
- Pages
- 869
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7923780
- OpenAlex
- W3133182888
- Cited by
- 113
- References
- 198
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 28 · 2023: 28 · 2022: 18 · 2021: 4
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Tiroler Wissenschaftsförderung (F.16962/5-2019)
- Austrian Science Fund (33249-B)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Keywords
- recurrent pregnancy loss, immunological risk factors, autoantibodies, natural killer cells, regulatory T cells, dendritic cells, plasma cells, corticosteroids, Intralipid, intravenous immunoglobulin, aspirin, heparin, idiopathic recurrent pregnancy loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.